Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Silexion Therapeutics (NASDAQ:SLXN), a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, will present at the 27th Annual H.C. Wainwright Global Investment Conference. The presentation is scheduled for September 10, 2025, at 2:00 PM ET at the Lotte New York Palace Hotel.
The company has uploaded an updated corporate presentation to their website's investor section. Management will be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.
Silexion Therapeutics (NASDAQ:SLXN), società biotecnologica in fase clinica che sviluppa terapie a interferenza RNA per tumori guidati da KRAS, presenterà al 27° Annuale H.C. Wainwright Global Investment Conference. L'intervento è previsto per il 10 settembre 2025 alle 14:00 ET presso il Lotte New York Palace Hotel.
La società ha caricato una presentazione aziendale aggiornata nella sezione investitori del proprio sito web. Il management sarà disponibile per incontri individuali con gli investitori durante la conferenza, prenotabili tramite i rappresentanti di H.C. Wainwright.
Silexion Therapeutics (NASDAQ:SLXN), compañía biotecnológica en fase clínica centrada en terapias de interferencia de ARN para cánceres impulsados por KRAS, presentará en la 27ª Conferencia Anual Global de Inversión H.C. Wainwright. La presentación está programada para el 10 de septiembre de 2025 a las 14:00 ET en el Lotte New York Palace Hotel.
La empresa ha subido una presentación corporativa actualizada en la sección de inversores de su sitio web. La dirección estará disponible para reuniones uno a uno con inversores durante la conferencia, que se pueden coordinar a través de los representantes de H.C. Wainwright.
Silexion Therapeutics (NASDAQ:SLXN), KRAS 유발 암을 표적으로 하는 RNA 간섭 치료제에 집중하는 임상 단계의 생명공학 기업이 제27회 H.C. Wainwright 글로벌 투자 콘퍼런스에서 발표합니다. 발표는 2025년 9월 10일 오후 2시(동부시간), 롯데 뉴욕 팰리스 호텔에서 예정되어 있습니다.
회사는 투자자 섹션에 최신 기업 프레젠테이션을 업로드했습니다. 경영진은 콘퍼런스 기간 중 투자자와의 1:1 미팅에 응할 예정이며, 해당 미팅은 H.C. Wainwright 담당자를 통해 예약할 수 있습니다.
Silexion Therapeutics (NASDAQ:SLXN), une société biotechnologique en phase clinique spécialisée dans les thérapies par interférence ARN pour les cancers à mutation KRAS, présentera lors de la 27e conférence annuelle mondiale H.C. Wainwright. La présentation est prévue le 10 septembre 2025 à 14h00 ET au Lotte New York Palace Hotel.
La société a mis en ligne une présentation d'entreprise mise à jour dans la rubrique investisseurs de son site web. La direction sera disponible pour des rencontres individuelles avec les investisseurs pendant la conférence ; ces rendez-vous peuvent être organisés via les représentants de H.C. Wainwright.
Silexion Therapeutics (NASDAQ:SLXN), ein klinisch fortgeschrittenes Biotech-Unternehmen, das sich auf RNA-Interferenz-Therapien für KRAS-getriebene Krebserkrankungen konzentriert, wird auf der 27. jährlichen H.C. Wainwright Global Investment Conference präsentieren. Die Präsentation ist geplant für den 10. September 2025 um 14:00 Uhr ET im Lotte New York Palace Hotel.
Das Unternehmen hat eine aktualisierte Unternehmenspräsentation im Investor-Bereich seiner Website hochgeladen. Das Management steht während der Konferenz für Einzelgespräche mit Investoren zur Verfügung; Termine können über die Vertreter von H.C. Wainwright arrangiert werden.
- None.
- None.
Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City.
Silexion's company presentation will take place on Tuesday, September 10, 2025, at 2:00 PM ET. An updated company presentation has been posted to Silexion's website in the Presentation & Events section of the Company’s investor site.
The Silexion management team will be available for in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with Silexion through their H.C. Wainwright representative or e-mail meetings@hcwco.com
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Contacts
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com
FAQ
When is Silexion Therapeutics (SLXN) presenting at the H.C. Wainwright Conference?
How can investors schedule meetings with Silexion management at the H.C. Wainwright Conference?
What type of therapies is Silexion Therapeutics developing?
Where can investors access Silexion's latest corporate presentation?
